Document:

EX-4.5

 Exhibit 4.5 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN
EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. 
 THIS
WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR THE SECURITIES LA\-VS OF ANY STATE OF THE UNITED STATES. THE
SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER APPLICABLE SECURITIES LAWS OR UNLESS OFFERED, SOLD, PLEDGED, HYPOTHECATED OR
TRANSFERRED PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THOSE LAWS. THE COMPANY SHALL BE ENTITLED TO REQUIRE AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED TO THE EXTENT THAT AN
OPINION IS REQUIRED PURSUANT TO THE AGREEMENT UNDER WHICH THE SECURITIES WERE ISSUED. 
 ADVANTAGENE, INC. 

WARRANT TO PURCHASE SERIES A CONVERTIBLE PREFERRED STOCK 

No. PA -      

                 Series A Preferred Shares 

April 5, 2016 
 Void
After April 5, 2021 
 THIS CERTIFIES THAT, for value received and subject to the terms and conditions set forth below, _______________, or
assigns (the “Holder”), is entitled to subscribe for and purchase a’: the Exercise Price (defined below) from Advantagene, Inc., a Delaware corporation (the “Company”)
                             (
    ,         ) shares of the Series A Convertible Preferred Stock of the Company, $0.01 par value (the “Preferred Stock”), subject to adjustment as
provided herein. 
 1. DEFINITIONS. As used herein, the following terms shall have the following respective meanings: 

(a) “Exercise Period” shall mean the period commencing on the date of issuance and ending five (5) years from such date,
unless sooner terminated as provided below. 
 (b) “Exercise Price” shall mean $3.20 per share, subject to adjustment
pursuant to Section 5 below. 
 (c) “Warrant Shares” shall mean the shares of the Company’s Series A
Convertible Preferred Stock issuable upon exercise of this Warrant, subject to adjustment pursuant to the terms herein, including but not limited to adjustment pursuant to Section 5 below. 

 2. EXERCISE OF WARRANT. 

2.1. Method of Exercise. The rights represented by this Warrant may be exercised in whole or in part at any time during the Exercise Period, by delivery
of the following to the Company: 
 (a) An executed Notice of Exercise in the form attached hereto; 

(b) Payment of the Exercise Price in cash or by check or wire transfer of immediately available funds; and 

(c) This Warrant. 
 Upon the exercise of the rights
represented by this Warrant, shares of Series A Convertible Preferred Stock shall be issued for the Warrant Shares so purchased, and shall be registered in the name of the Holder or persons affiliated with the Holder, if the Holder so designates, on
or before the third (3rd) business day after the rights represented by this Warrant shall have been so exercised and shall be issued in certificate form and delivered to the Holder, if so
requested. 
 The person in whose name any Warrant Shares are to be issued upon exercise of this Warrant shall be deemed to have become the holder of record
of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of issuance of the shares of Series A Convertible Preferred Stock, except that, if the date of such surrender and
payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next succeeding date on which the stock transfer books are open. 

2.2. Partial Exercise. If this Warrant is exercised in part only, the Company shall, upon surrender of this Warrant, execute and deliver, within 10
days of the date of exercise, a new Warrant evidencing the rights of the Holder, or such other person as shall be designated in the Notice of Exercise, to purchase the balance of the Warrant Shares purchasable hereunder. If the Holder exercises this
Warrant or attempts to exercise this Warrant before the Company shall have delivered to the Holder a new Warrant as contemplated above, then the Holder shall be deemed to have validly exercised this Warrant pursuant to this
Section 2 without having complied with the requirements of Section 2.1(c). In no event shall this Warrant be exercised for a fractional Warrant Share, and the Company shall not distribute a
Warrant exercisable for a fractional Warrant Share. Fractional Warrant Shares shall be treated as provided in Section 7 hereof. 

3. COVENANTS OF THE COMPANY. 
 3.1. Covenants as to
Warrant Shares. If at any time the number of authorized but unissued shares of Series A Convertible Preferred Stock shall not be sufficient to permit exercise of this Warrant, the Company will take such corporate action as may, in the opinion of
its counsel, be necessary to increase its authorized but unissued shares of Series A Convertible Preferred Stock (or other securities as provided herein) to such number of shares as shall be sufficient for such purposes. 

  
 2 

 3.2. No Impairment. Except and to the extent as waived or consented to by the Holder or otherwise in
accordance with Section 2 hereof, the Company will not, by amendment of its Certificate of Incorporation (as such may be amended from time to time), or through any means, avoid or seek to avoid the observance or performance
of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all the provisions of this Warrant and in the taking of all such action as may be necessary or appropriate in
order to protect the exercise rights of the Holder against impairment. 
 3.3. Notices of Record Date. In the event of any taking by the Company of a
record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend which is the same as cash dividends paid in previous quarters) or other
distribution, the Company shall mail to the Holder, at least ten (10) days prior to the date specified herein, a notice specifying the date on which any such record is to be taken for the purpose of such dividend or distribution. 

4. REPRESENTATIONS OF HOLDER. 
 4.1. Acquisition of
Warrant for Personal Account. The Holder represents and warrants that it is acquiring the Warrant and the Warrant Shares solely for its account for investment and not with a present view toward the public distribution of said Warrant or Warrant
Shares or any part thereof and has no intention of selling or distributing said Warrant or Warrant Shares or any arrangement or understanding with any other persons regarding the sale or distribution of said Warrant, except as would not result in a
violation of the Securities Act. The Holder will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) the Warrant except in accordance
with the Securities Act and will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) the Warrant Shares except in accordance with the
provisions of the Securities Act. 
 4.2. Securities Are Not Registered. 

(a) The Holder understands that the offer and sale of the Warrant or the Warrant Shares have not been registered under the Securities Act on the basis
that no distribution or public offering of the stock of the Company is to be effected. The Holder realizes that the basis for the exemption may not be present if, notwithstanding its representations, the Holder has a present intention of acquiring
the securities for a fixed or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the securities. The Holder has no such present intention. 

(b) The Holder recognizes that the Warrant and the Warrant Shares must be held indefinitely unless they are subsequently registered under the
Securities Act or an exemption from such registration is available. The Holder recognizes that the Company has no obligation to register the Warrant or the Warrant Shares, or to comply with any exemption from such registration. 

(c) The Holder is aware that neither the Warrant nor the Warrant Shares may be sold pursuant to Rule 144 adopted under the Securities Act unless
certain conditions are met, including, among other things, the existence of a public market for the shares, the availability of certain current 

  
 3 

 
public information about the Company, the resale following the required holding period under Rule 144 and the number of shares being sold during any three-month period not exceeding specified
limitations. Holder is aware that any such sale made in reliance on Rule 144, if Rule 144 is available, may be made only in accordance with the terms of Rule 144. 

4.3. Disposition of Warrant and Warrant Shares. 
 The
Holder understands and agrees that all certificates evidencing the Warrant Shares to be issued to the Holder may bear a legend in substantially the following form: 

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR ANY APPLICABLE STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE,
PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT
REQUIRED OR UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A OF SUCH ACT. 
 5. CHANGES IN OUTSTANDING SHARES. In the event of changes in the
outstanding Series A Convertible Preferred Stock of the Company by reason of stock dividends, split-ups, recapitalizations, reclassifications, combinations or exchanges of shares, separations, reorganizations,
liquidations, or the like, the number and class of shares available under the Warrant in the aggregate and the Exercise Price shall be correspondingly adjusted to give the Holder of the Warrant, on exercise for the same aggregate Exercise Price, the
total number, class, and kind of shares as the Holder would have owned had the Warrant been exercised prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment. The form of this Warrant need not
be changed because of any adjustment in the number, class, and kind of shares subject to this Warrant. The Company shall promptly provide a certificate from an authorized officer notifying the Holder in writing of any adjustment in the Exercise
Price and/or the total number, class, and kind of shares issuable upon exercise of this Warrant, which certificate shall specify the Exercise Price and number, class and kind of shares under this Warrant after giving effect to such adjustment. 

6. FUNDAMENTAL TRANSACTIONS. If any capital reorganization, reclassification of the capital stock of the Company, consolidation or merger of the
Company with another entity in which the Company is not the survivor, or sale, transfer or other disposition of all or substantially all of the Company’s assets to another entity shall be effected (any such transaction being hereinafter
referred to as a “Fundamental Transaction”), then the Company shall ensure that lawful and adequate provision shall be made whereby the Holder shall thereafter have the right to purchase and receive upon the basis and upon
the terms and conditions herein specified and in lieu of the Exercise Shares immediately theretofore issuable upon exercise of this Warrant, such shares of stock, securities or assets as would have been issuable or payable with respect to or in
exchange for a number of Exercise Shares equal to the number of Exercise Shares immediately theretofore issuable upon exercise of this Warrant, had such reorganization, reclassification, consolidation, merger, sale, transfer or other disposition not
taken place, and in any such case appropriate provision shall be made with respect to the rights and interests of the Holder to the 

  
 4 

 
end that the provisions hereof (including, without limitation, provision for adjustment of the Exercise Price) shall thereafter be applicable, as nearly equivalent as may be practicable in
relation to any share of stock, securities or assets thereafter deliverable upon the exercise thereof. The Company shall not effect any such consolidation, merger, sale, transfer or other disposition unless prior to or simultaneously with the
consummation thereof the successor entity (if other than the Company) resulting from such consolidation or merger, or the entity purchasing or otherwise acquiring such assets or other appropriate corporation or entity shall assume the obligation to
deliver to the Holder, at the last address of the Holder appearing on the books of the Company, such shares of stock, securities or assets as, in accordance with the foregoing provisions, the Holder may be entitled to purchase, and the other
obligations under this Warrant. The provisions of this Section 6 shall similarly apply to successive reorganizations, reclassifications, consolidations, mergers, sales, transfers or other dispositions, each of which
transactions shall also constitute a Fundamental Transaction. 
 7. FRACTIONAL SHARES, ADJUSTMENT OF EXERCISE PRICE. No fractional shares shall be
issued upon the exercise of this Warrant as a consequence of any adjustment pursuant hereto. All Warrant Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining whether the exercise would
result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such
fraction a sum in cash equal to the product resulting from multiplying the then current fair market value of an Exercise Share by such fraction. No adjustment in the Exercise Price shall be required unless such adjustment would require an increase
or decrease of at least $0.0001; provided, however, that any adjustments which by reason of this Section 7 are not required to be made shall be carried forward and taken into account in any subsequent adjustment. All
calculations under this Section 7 shall be made to the $0.01 or to the nearest 1/100th of a share, as the case may be. 
 8. NO
STOCKHOLDER RIGHTS. This Warrant in and of itself shall not entitle the Holder to any voting rights or, except as otherwise set forth herein, other rights as a stockholder of the Company. 

9. TRANSFER OF WARRANT. Subject to applicable laws and compliance with Section 4.3 hereof, this Warrant and all rights
hereunder are transferable, by the Holder in person or by duly authorized attorney, upon delivery of this Warrant and the form of assignment attached hereto to any transferee designated by Holder. 

10. LOST, STOLEN, MUTILATED OR DESTROYED WARRANT. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to
indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or destroyed. Any such
new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone. 

11. MODIFICATIONS AND WAIVER. Except as expressly provided herein, neither this Warrant nor any term hereof may be amended, waived, discharged or
terminated other than by a written instrument signed by the party against whom enforcement of any such amendment, waiver, discharge or termination is sought. 

  
 5 

 12. NOTICES, ETC. All notices or other communications required or permitted hereunder shall be in
writing and shall be deemed given or delivered: (i) when delivered personally; (ii) one business day following deposit with a recognized overnight courier service, provided such deposit occurs before the deadline imposed by that
service for overnight delivery; (iii) when transmitted, if sent by facsimile copy or electronic mail, provided confirmation of receipt is received by sender, in each case provided the communication is addressed to the intended recipient
thereof as set forth below: 
 If to Holder, to: 

National Securities Corporation 

410 Park Avenue, 14th Floor 

New York, NY 10022 
 Fax: (212)380-2828 
 Tel: (212) 380-2819 

If to the Company to: 

Advantagene, Inc. 
 440 Lexington
Street 
 Auburndale, MA 02466 

Tel: [***] 
 Attention: Stephen
Rocamboli 
 Email: [***] 
 or
to such other address of which written notice is given to the parties. 
 13. ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute
acceptance of and agreement to all of the terms and conditions contained herein. 
 14. GOVERNING LAW. This Warrant and all rights, obligations and
liabilities hereunder shall be governed by the laws of the State of Delaware without regard to the principles of conflict of laws. 
 15. DESCRIPTIVE
HEADINGS. The descriptive headings of the several paragraphs of this Warrant are inserted for convenience only and do not constitute a part of this Warrant. The language in this Warrant shall be construed as to its fair meaning without regard to
which party drafted this Warrant. 
 16. SEVERABILITY. The invalidity or unenforceability of any provision of this Warrant in any jurisdiction shall
not affect the validity or enforceability of such provision in any other jurisdiction, or affect any other provision of this Warrant, which shall remain in full force and effect. 

  
 6 

 17. ENTIRE AGREEMENT. This Warrant constitutes the entire agreement between the parties pertaining to
the subject matter contained in it and supersede all prior and contemporaneous agreements, representations, and undertakings of the parties, whether oral or written, with respect to such subject matter. 

[Signature Page Follows] 

  
 7 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its duly authorized officer
as of April 5, 2016. 
 ADVANTAGENE, INC. 
  

			
	By:	 	 /s/ Estuardo Aguilar-Cordova

		 	 Estuardo Aguilar-Cordova,
 Chief Executive
Officer

 NOTICE OF EXERCISE 

TO: ADVANTAGENE, INC. 
 (1) The undersigned hereby
elects to: 
 ☐ purchase                  shares of the Series
A Convertible Preferred Stock of Advantagene, Inc. (the “Company”) pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full for such shares, together with all applicable
transfer taxes, if any. 
 (2) Please issue a certificate or certificates representing said shares of Series A Convertible Preferred Stock in the
name of the undersigned or in such other name as is specified below: 
  
  

 
 (Name) 

 
  
  

(Address) 
 (3) The undersigned represents that
(i) the aforesaid shares of Series A Convertible Preferred Stock are being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned
has no present intention of distributing or reselling such shares in violation of the Securities Act of 1933, as amended (the “Securities Act”); (ii) the undersigned is aware of the Company’s business affairs and
financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its investment in the Company; (iii) the undersigned is experienced in making investments of this type and
has such knowledge and background in financial and business matters that the undersigned is capable of evaluating the merits and risks of this investment and protecting the undersigned’s own interests; (iv) the undersigned understands that
the shares of Series A Convertible Preferred Stock issuable upon exercise of this Warrant have not been registered under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act, which exemption
depends upon, among other things, the bona fide nature of the investment intent as expressed herein, and, because such securities have not been registered under the Securities Act, they must be held indefinitely unless subsequently registered under
the Securities Act or an exemption from such registration is available; (v) the undersigned is aware that the aforesaid shares of Series A Convertible Preferred Stock may not be sold pursuant to Rule 144 adopted under the Securities Act unless
certain conditions are met and until the undersigned has held the shares for the time period prescribed by Rule 144, that among the conditions for use of Rule 144 is the availability of current information to the public about the Company; and
(vi) the undersigned agrees not to make any disposition of all or any part of the aforesaid shares of Series A Convertible Preferred Stock unless and until there is then in effect a registration statement under the Securities Act covering such
proposed disposition and such disposition is made in accordance with said registration statement, or the undersigned has furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, to the effect that such disposition

 
is not required to be registered pursuant to the Securities Act or any applicable state securities laws; provided, that no opinion shall be required for any disposition made or to be made
in accordance with the provisions of Rule 144. 
  
  

					
	  
 Date
	 		  	  
 Signature

		 		  	
		 		  	  
 Print nameEX-10.7

 Exhibit 10.7 

EXCLUSIVE LICENSE AGREEMENT between 

ADVANTAGENE, INC. 
 and

 VENTAGEN, L.L.C. 
  

 EXCLUSIVE LICENSE AGREEMENT 

This Exclusive License Agreement (hereinafter referred to as this “Agreement”), effective as March 1, 2014 (the “Effective
Date”), is entered into by and between Advantagene, Inc., a corporation duly incorporated under the laws of Delaware and having a place of business at 440 Lexington Street, Auburndale, MA (“Licensor”), and Ventagen, LLC., a
Massachusetts limited liability company, having a place of business at 160 Paulson Road, Waban MA (the “Company”). 
 WHEREAS,
Licensor is the sole owner of all right, title and interest in the Technology (as defined herein), the Patent Rights (as defined herein), and Know How (as defined herein) related thereto; 

WHEREAS, the Licensor licensed certain rights to the Technology for development and commercialization in Mexico and Central America to
Ellka Holding, LLC d/b/a Advantagene Holdings, LLC (“AHI”) on or about February, 2014 (the “Original License”); 

WHEREAS, the Licensor and AHI have terminated the Original License contemporaneously with the execution of this Agreement and the
Original License is no longer in force and effect; and 
 WHEREAS, the Company wishes to acquire the Technology for development and
commercialization in Mexico and Central America and the Licensor wants to enable the Company to do so pursuant to the terms of this Agreement. 

NOW, THEREFORE, in consideration of the foregoing recitals, the premises and the mutual covenants contained herein, the parties hereto,
intending to be legally bound, agree as follows: 
 Article 1 Definitions 

For the purposes of this Agreement, the following words and phrases shall have the following meanings: 

 

	1.1	 “Affiliate” 

means, with respect to any Person, any other Person which directly or indirectly controls, is controlled by, or is under common control with, such Person. A
Person shall be regarded as in control of another Person if it owns, or directly or indirectly controls, at least [***] percent ([***]%) of the voting stock or other ownership interest of the other Person, or if it directly or indirectly possesses
the power to direct or cause the direction of the management and policies of the other Person by any means whatsoever. 
  

	1.2	 “Applicable Law(s)” 

means, with respect to the United States, the FDCA (as defined below), all regulations promulgated thereunder, and all other applicable laws, rules,
regulations and guidelines within the Territory that apply to the import, export, research and development, manufacture, marketing, distribution, or 

 
sale of Licensed Products in the Field of Use in the Territory or the performance of either party’s obligations under this Agreement (including disclosure obligations as required by the
United States Securities and Exchange Commission or other comparable exchange or securities commission having authority over a party) to the extent applicable and relevant to such party. 

 

	1.3	 “Competent Authority(ies)” 

means collectively the entities in each country in the Territory responsible for (a) the regulation of medicinal products intended for human use or the
establishment, maintenance and/or protection of rights related to Licensed Products and any successor entities thereto including but not limited to COFEPRIS in Mexico, (b) the establishment, maintenance and/or protection of rights related to
the Patent Rights, including the United States Patent and Trademark Office (“USPTO”), and (c) any other applicable regulatory or administrative agency in any country in the Territory that is comparable to, or a counterpart of, the
foregoing. 
  

	1.4	 “Development” 

means the Company’s, its Affiliates’, or Sublicensees’ use of commercially reasonable efforts to secure Marketing Authorizations for Licensed
Products in the Territory. 
  

	1.5	 “FDCA” 

means the United States’ Federal Food, Drug, and Cosmetic Act, as amended, and the regulations promulgated with respect thereto. 

 

	1.6	 “FDA” 

means the United States Food and Drug Administration and any successor entity thereto. 

 

	1.7	 “Field of Use” 

means the prevention or treatment of cancer in humans and any use in animals. 
  

	1.8	 Intentionally deleted. 

 

	1.9	 “Governmental Approval(s)” 

means any and all permits, licenses, approvals, and authorizations required by any Competent Authority as a prerequisite to the development, manufacturing,
packaging, marketing, distribution and selling of a Licensed Product in the Field of Use in the Territory. 
  

	1.10	 “IND(s)” 

means an investigational new drug application as defined in 21 C.F.R. Part 312 et seq in the United States (as may be amended, supplemented or replaced
from time to time), or equivalent application to any Competent Authority of any other country in the Territory, to commence clinical testing of a drug, including but not limited to any amendments, supplements, or supporting correspondence with
respect thereto. 

  
 2 

	1.11	 “Improvements” 

shall mean any modification or enhancement of a Licensed Product, or any inventions, or discoveries (whether patentable or not), information, and data, owned
or controlled by Licensor at any time during the Term, which would be reasonably useful or necessary for the use or sale of any Licensed Product, or the practice of that would infringe a Valid Claim within the Patent Rights or violate data and
market exclusivity rights provided by any Competent Authority in the United States or the Territory. 
  

	1.12	 “Know-how” 

shall mean all tangible or intangible information and know-how (other than that which is the subject of a Valid Claim
in the Patent Rights), whether patentable or not (but which has not been patented), related to the Technology, the Licensed Product, or any Improvement or which is reasonably useful to or necessary for the Company to develop or commercialize any
Licensed Product (including but not limited to: trade secrets, formulations, protocol, results of experimentation, in vitro, preclinical or clinical design, information or results, other proprietary materials, processes, including but not limited to
manufacturing processes, data, drawings and sketches, designs, testing and test results, regulatory information of a like nature), owned or controlled by Licensor as of the Effective Date or which Licensor obtains the right to disclose and license
to the Company during the Term. 
  

	1.13	 “Licensed Product(s)” 

means any product that (i) cannot be manufactured, used or sold, in whole or part, without infringing one or more Valid Claims included within the Patent
Rights in the country in which the product is made, used, leased, imported, exported, offered for sale or sold and/or (ii) incorporates the Know-how or the Technology. 

 

	1.14	 “Marketing Authorization” 

means all necessary and appropriate regulatory approvals, including but not limited to BLAs and reimbursement and pricing approvals, to allow a Licensed
Product to be marketed and sold in the Field of Use in a particular country in the Territory. 
  

	1.15	 “Milestone Payment” 

means the payments set out in Article 6.6. 
  

	1.16	 “BLA” 

means a biologies license application (equivalent to that defined in Title 21 of the U.S. Code of Federal Regulations, as amended) to any Competent Authority
of any other country in the Territory, to commence commercial sale and marketing of a drug for human use, including but not limited to any amendments, supplements, or supporting correspondence and related documents with respect thereto. 

  
 3 

	1.17	 “Net Sales” 

shall have the meaning set out below: 
  

	 	1.17.1	 “Net Sales” shall mean the total gross receipts for sales of Licensed Products to customers who are
not Affiliates, or are Affiliates, but are end users of the Licensed Products, by or on behalf of the Company or any of its Affiliates or Sublicensees (if applicable), whether invoiced or not, less only the sum of the following:

  

	 	(a)	 usual trade discounts to customers, including but not limited to cash, quantity and trade discounts, rebates
and other price reductions for such Licensed Product given to such customers; 

  

	 	(b)	 amounts allowed or credited on charge-backs and/or returns; 

 

	 	(c)	 bad debt deductions and uncollectible amounts actually written off during the accounting period;

  

	 	(d)	 wholesaler discounts and government chargebacks 

 

	 	1.17.2	 Components of Net Sales (and the deductions listed above) shall be determined in the ordinary course of
business in accordance with GAAP. 

  

	 	1.17.3	 Notwithstanding anything herein to the contrary, the transfer of a Licensed Product to an Affiliate,
Sublicensee, or other Third Party in connection with the research, development or testing of a Licensed Product or for purposes of resale shall not be considered a sale of a Licensed Product under this Agreement. Nor shall the transfer of Licensed
Product solely for indigent or similar public support or compassionate use programs be considered a sale of Licensed Product under this Agreement. 

  

	 	1.17.4	 In the case of discounts on “bundles” of separate products or services which include Licensed
Products, the Company may discount (or enable its Affiliates and Sublicensees to discount) the bona fide list price of a Licensed Product by the average percentage discount of all products of the Company and/or its Affiliates and Sublicensees in a
particular “bundle”, calculated as follows: 

  

							
	Average percentage
discount on a
particular “bundle”	  	=	  	1 - (X/Y) x 100	  	

 where X equals the total discounted price of a particular “bundle” of products, and Y equals
the sum of the undiscounted bona fide list prices of each unit of every product in such “bundle”. The Company shall provide Licensor documentation reasonably supporting such average discount with respect to each “bundle.” If a
Licensed Product in a “bundle” is not sold separately, and 

  
 4 

 
no bona fide list price exists for such Licensed Product, the parties to work together in good faith to determine a reasonable imputed list price for such Licensed Product and Net Sales with
respect thereto shall be based on such imputed list price. 
  

	1.18	 “Patent Rights” 

means 
  

	 	1.18.1	 all U.S. and foreign patents and patent applications owned or controlled by the Licensor during the Term that
cover the Technology in the Territory (the “Patents”); 

  

	 	1.18.2	 any and all U.S. or foreign patents, patent applications, or other rights issuing from, or filed subsequent to
the date of this Agreement, based on or claiming priority to or from the applications, patents, and rights included in the Patents or relating to any Improvement, including but not limited to continuations, continuations in part, divisional,
reexaminations, extensions, reissues, substitutions, renewals, supplementary protection certificates, registrations, and confirmations of any of the foregoing, and any patents resulting from any application or right included in Articles 1.18.1 or
1.18.2; 

  

	 	1.18.3	 any information owned or controlled by the Licensor during the Term reasonably necessary to file and obtain
issuance of valid patent claims relating to the use, manufacture, development, administration, delivery, formulation, dosing, packaging, and handling of Licensed Products. 

The parties shall use commercially reasonable efforts to ensure that the Company is aware of and has an accurate list of the Patents, such list to be amended
in writing from time to time to reflect the foregoing, provided that any failure to do so shall not limit the scope of the definition of Patent Rights established above. 
  

	1.19	 “Person” 

means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint venture,
non-profit organization, pool, syndicate, sole proprietorship, unincorporated organization, university, governmental authority or any other form of entity not specifically listed herein. 

 

	1.20	 Intentionally deleted. 

 

	1.21	 “Registration(s)” 

means any and all permits, licenses, authorizations, registrations or regulatory approvals (including, but not limited to, IND or BLA) required and/or granted
by any Competent Authority as a prerequisite to the development, manufacturing, packaging, shipping, marketing and/or selling of any product. 

  
 5 

	1.22	 “Royalty Term” 

means, on a country-by-country and Licensed Product-by-Licensed Product basis, the period commencing on the Effective Date and ending on the later to occur of (i) the date of the last to expire Valid Claim contained in the Patent Rights covering a
Licensed Product in such country (such expiration including, for purposes hereof, the date upon which no Valid Claims remain with respect to a particular country, even if such date occurs prior to patent issuance), provided that, for purposes of
this definition, any Valid Claim that has not issued but has been pending more than [***] years from filing shall be deemed expired (and not a Valid Claim); (ii) [***] years from the receipt of Marketing Authorization in the applicable country;
and (iii) the date a generic version of a Licensed Product that is manufactured, owned or controlled by a Third Party is granted a Market Authorization. 
  

	1.23	 “Sublicensee” 

means a Third Party that has entered in to an agreement with the Company licensing to such Third Party any of the rights granted to the Company by the Licensor
pursuant to Article 2.1, or a Third Party that has entered into a license agreement with any such Sublicensee licensing such Third Party the rights granted to the Company by the Licensor and granted to such subsequent Third Party licensee by the
Sublicensee. 
  

	1.24	 “Technology” 

means the delivery of the herpes derived TK protein to tumors or other tissues via a viral vector together with the delivery of a prodrug with the intent to
cause a cytotoxic and immunogenic anti-tumoral response, together with (a) any derivatives, parts or polymorphisms (including without limitation splice variants) of any such vector and (b) nucleotide sequences that encode any of the
foregoing”.] 
  

	1.25	 “Term” 

has the meaning set out in Article 11.1. 
  

	1.26	 “Territory” 

means the countries of Mexico, Belize, Guatemala, Honduras, El Salvador, Nicaragua, Costa Rica, Panama, Columbia and Bolivia. 

 

	1.27	 “Third Party” 

means any Person other than the Licensor, the Company and their respective Affiliates. 

 

	1.28	 “Valid Claim” 

means any pending or issued claim included within the Patent Rights that has been filed in good faith and has not been withdrawn, permanently revoked,
abandoned nor deemed unenforceable, unpatentable, or invalid by a decision of a court or other governmental agency of competent jurisdiction that is unappealable or unappealed in the time allowed for appeal, and which has not been admitted to be
invalid or unenforceable through reissue or disclaimer or otherwise. 

  
 6 

 Article 2 License Grant 

 

	2.1	 Grant of License 

Licensor hereby grants to the Company an exclusive license, with rights to grant sublicense as further described below, to practice under the Patent Rights and
to utilize the Know-how solely in the Territory and in the Field of Use, including to: 
  

	 	2.1.1	 conduct research, use, have used, import, have imported, export, have exported, offer for sale, have sold,
sell, distribute and market Licensed Products to the full end of the Royalty Term, unless sooner terminated pursuant to the terms of this Agreement, provided, however, that the Company, subject to Article 2.1.4, shall not have the
right to make, have made or otherwise manufacture Licensed Products; and 

  

	 	2.1.2	 sublicense to third parties, through multiple tiers, in accordance with Article 2.2 below, the rights granted
under Article 2.1.1. 

  

	 	2.1.3	 Exclusivity. The Licensor and its Affiliates will not commercialize Licensed Product in the Territory in
the Field of Use. The Licensor may not grant licenses to Third Parties to develop, use or sell Licensed Products for use in both the Territory and the Field of Use. The Company covenants that it and its Affiliates and sublicensees shall not
manufacture, develop or commercialize Licensed Products or any product incorporating the Technology except as expressly provided in this Agreement, including but not limited to, outside of the Territory. Licensor retains exclusive rights relating to
the Technology and Licensed Products outside of the Territory and Field of Use. The sale of Licensed Products by the Company, its Affiliates or sublicensees outside of the Territory shall be a material breach of this Agreement by the Company (with
the exception of de minimis unintentional sales). The Company covenants it will not sell any Licensed Products for export outside the Territory and will include (i) as a covenant of all purchasers of Licensed Products that such customer will
not export Licensed Products outside the Territory and (ii) that Licensor is a third party beneficiary of such covenant and can sue for its breach. 

  

	 	2.1.4	 Conditional Right to Manufacture Licensed Products in the Territory. If the Licensor is unable or
unwilling to manufacture and timely supply Licensed Products to the Company in sufficient quantities to meet commercial demand in the Territory, as determined by reasonable forecasts provided by the Company to the Licensor at least [***] months in
advance of its anticipated commercial requirements, then the Company shall have the right, but not the obligation, to make or have made Licensed Product in the Territory to enable the Company to maintain an adequate commercial supply of Licensed
Products in the Territory. 

  
 7 

	 	2.1.5	 No right to set Wholesale Price of Licensed Products. As a condition of the Agreement or any sublicense
Agreement, the Company and any Sublicensee hereby agrees (in the case of the Company) and will agree (in the case of any Sublicensee) that it will not set a wholesale price for any Licensed Product in the Territory that is less than the wholesale
price for the Licensed Product in the United States. A breach of this 2.1.5 by the Company or its Sublicensee shall be a material breach of this Agreement. Notwithstanding the foregoing, the Company may provide discretionary and usual rebates,
discounts, chargebacks and other price reductions to its customers and in support of indigent use and compassionate use programs. 

  

	2.2	 Sublicenses 

  

	 	2.2.1	 The Company shall have the right to sublicense rights granted in Article 2.1 in its sole discretion, and each
Sublicensee shall have the right to grant further sublicenses in their sole discretion, provided, however, that (a) Licensor shall be notified of and provided a copy of any and all granted sublicenses (including those agreements
between Sublicensees); (b) any and all sublicenses shall be consistent with and subject to the terms of this Agreement; and (c) notwithstanding the grant of a sublicense, the Company shall remain responsible for the complete and faithful
performance of all the covenants and obligations under this Agreement, and the Company shall take prompt and reasonable corrective action against any Sublicensee to end any action or omission by the Sublicensee which, if committed by Company would
be a breach of an obligation of Company under this Agreement and to use reasonable efforts to mitigate any harm or damages caused to Licensor by such action or omission, including where warranted termination of the sublicense. All sublicenses
granted under this Article 2.2.1 shall survive and be automatically assigned to Licensor upon termination of this Agreement, provided however, Licensor shall not be obligated to incur any obligations in excess of those of Licensor to the Company
contained herein. 

  

	 	2.2.2	 No Sublicensing of Manufacturing Rights. Notwithstanding Article 2.2.1, the Company may not and will not
sublicense its rights to manufacture or otherwise make or have made Licensed Products in the Territory granted to it under Article 2.1.4. 

Article 3 Technology and Regulatory Transfer 
  

	3.1	 Technology and Regulatory Transfer 

Upon execution of this Agreement, Licensor shall provide the Company access to and the right to reference, at no additional cost, all Know-how, which shall include but not be limited to all pre-clinical or clinical data, trade secrets, human safety data, preliminary efficacy data, and other regulatory data
related to any Licensed Product in its possession, in each case that may reasonable be required by the Company to develop and commercialize Licensed Products in the Territory. 

  
 8 

 Article 4 Regulatory Compliance 

 

	4.1	 Ownership and Maintenance of Governmental Approvals 

 

	 	4.1.1	 The Company will own all Marketing Authorizations for each country in the Territory for Licensed Products.
Without limiting the generality of the foregoing, the Company shall prepare and submit in its own name and at its expense BLAs (or its equivalent) with the appropriate Competent Authorities in the Territory’ and any other equivalent application
with the Competent Authorities in other countries in the Territory. 

  

	 	4.1.2	 The Company shall secure and maintain in good standing, at its sole cost and expense, any and all Registrations
and Governmental Approvals (including, Marketing Authorizations, licenses, permits and consents, facility licenses and permits required by Applicable Laws or by the applicable Competent Authorities) necessary and/or required for the Company to
perform its obligations under this Agreement and use commercially reasonable efforts at its cost and expense to secure and maintain any variations and renewals thereof. The Company shall promptly notify the Licensor of any written or oral notices
received from, or inspections by, any Competent Authority relating to any such Governmental Approvals. 

  

	4.2	 Rights of Reference 

Each party shall grant and hereby grants to the other a free-of-charge right
and license to reference and use and have full access to all preclinical and clinical data, information, and results (including source documentation like patient case report forms), Registrations, Governmental Approvals, Marketing Authorizations,
and all other regulatory documents relating to or useful for the development and commercialization of the Technology and Licensed Products, including but not limited to any IND and BLA, and any supplements, amendments or updates to the foregoing,
where such regulatory documents are owned, licensed, or controlled by the other party (the “Right of Reference”). Notwithstanding the foregoing, subject to Article 2.1.4, in the case of the Company, the Right of Reference to chemistry,
manufacturing and controls information shall be limited to only that data and information required to develop and commercialize Licensed Products in the Territory, including to support INDs or Marketing Authorizations, and shall not be used for the
manufacturing of the Technology or any Licensed Product. Each party may license the Right of Reference to Affiliates and to Sublicensees to the extent it is reasonably required to develop and commercialize (but in the case of the Company, not
manufacture) Licensed Products in their respective Territory. 
 Article 5 Development and Commercialization 

 

	5.1	 Development 

The Company shall use commercially reasonable efforts to complete the Development of Licensed Products in the Territory in the Field, including:
(a) conducting all required pre-clinical studies including toxicology studies; (b) conducting all required activities related to human clinical trials; (c) conducting all required marketing,
promotion, sales, and distribution of Licensed Products; and 

  
 9 

 
the (d) filing and maintaining any and all regulatory filings. Registrations, applications and Government Approvals and Marketing Authorizations covering any of the foregoing activities and
other related regulatory activities. All activities relating to Development and commercialization under this Agreement shall be undertaken at Company’s sole cost and expense, except as otherwise expressly provided in this Agreement. The Right
of Reference in Article 4.2 above shall include all data, results and information generated by the Company or its Sublicensees in the performance of the Development. 
  

	5.2	 Commercialization 

The Company shall, promptly following receipt of the necessary Marketing Authorizations, use commercially reasonable efforts to, itself or through the
activities of its Sublicensees and Affiliates, commence marketing of, and to distribute, promote, market, sell and commercialize thereafter, Licensed Products in the Territory within Field of Use. 

Article 6 Royalties and Other Consideration 
  

	6.1	 Manufacturing Transfer Price. 

The Company hereby agrees to purchase all of its clinical and commercial supply of Licensed Products exclusively from the Licensor for a per unit fee equal to
cost plus [***]% of the Average Quarterly Selling Price of the Licensed Products in the Territory to the full end of the Royalty Term in each country in the Territory. The “Average Quarterly Selling Price” shall mean the listed per unit
wholesale price less average per unit discounts and rebates for each fiscal quarter, provided, however, the Average Quarterly Selling Price shall never be less than U.S. $[***] per unit dose and never more than U.S. $[***] per unit dose. 

 

	6.2	 Reduced Transfer Price Under Certain Circumstances 

If Licensor is unable or unwilling to manufacture and timely provide Licensed Products to the Company in sufficient quantities to meet commercial demand in the
Territory and the Company and its Sublicensees are required to manufacture and distribute Licensed Products themselves (as further described in Article 2.1.4), then the Company shall remit to the Licensor U.S. $[***] per unit dose sold by it, its
affiliates, agents or sublicensees or end users, even if such Licensed Product is sold in combination with other products, to the full end of the Royalty Term in each country in the Territory. 

 

	6.3	 License Fee 

As further consideration for the license granted hereunder, the Company will remit U.S. $[***] (the “License Fee”) to the Licensor no later than
[***] after achieving aggregate Nets Sales equal to U.S. $[***] (as determined using the currency exchange procedures in Article 6.7). The License Fee shall be [***] ($[***]) Dollars that are incurred by it to obtain the first Marketing
Authorization for a Licensed Product in the Territory. 
  

	6.4	 Research and Development Support. 

The Company will remit U.S. $[***] to the Licensor (the “R&D Fee”). 

  
 10 

	6.5	 Place of Payment, Taxes and Conversions 

All payments under this Agreement shall be paid in United States dollars, unless otherwise required by law, at such place as Licensor may reasonably designate
consistent with applicable laws and regulations. Any taxes, duties, or other levies which the Company, its Affiliate or any Sublicensee shall, in its reasonable discretion, be required by law to pay or withhold on remittance of any payment(s) due
under this Agreement shall be deducted from such payment(s) to Licensor. Any such taxes, levies, or duties required under applicable law to be paid or withheld shall be an expense of, and borne solely by, Licensor. The Company will use commercially
reasonable efforts to secure and send to Licensor proof of any such taxes, duties or other levies withheld and paid by the Company for the benefit of Licensor, and cooperate, at Licensor’s expense, with any reasonable request to help ensure
that amounts withheld and/or paid are reduced and/or recovered to the extent permitted by the relevant jurisdiction. If any currency conversion shall be required in connection with the payment of royalties hereunder, such conversion shall be made by
using the exchange rate prevailing at Citibank, N.A. in New York, New York on the last business day of the calendar quarterly reporting period to which such royalty payments relate. In each country where the local currency is blocked and cannot be
removed from the country under such country’s applicable law, royalties accrued with respect to that country shall be paid to Licensor in such country in local currency by deposit in a local bank designated by Licensor, unless the parties
otherwise agree 
  

	6.6	 Time for Payment 

The Company shall pay to Licensor the royalties and other payments due and payable under this Agreement on a quarterly basis, due [***] days after the
conclusion of each calendar quarter, and shall provide the documents and records referred to in Article 7.1 along with such payment. If no royalties or other payments that may be due to Licensor under this Agreement shall be due, the Company shall
not be required to make a report pursuant to Article 7.1. 
  

	6.7	 Interest 

Amounts which are not paid when due shall accrue interest from the due date until paid, at a rate equal to the then prevailing prime rate of Citibank, N.A.,
plus [***] percent ([***]%). 
 Article 7 Reports and Records 

 

	7.1	 Record Keeping and Retention. 

Commencing as of the Effective Date, the Company and its Affiliates and Sublicensees shall keep for at least [***] years from the end of the calendar year to
which they pertain complete and accurate records of the Development and sales or other commercial disposition by Company or its Affiliates and Sublicensees, as the case may be, of each Licensed Product, in sufficient detail to allow the accuracy of
the payments made or owed under this Agreement to be confirmed. Subject to the other terms of this Article 7, at the request of Licensor, which shall not be made more frequently than once per calendar year during the Term, upon at least [***]
days’ prior written notice from Licensor, and at the expense of Licensor (except as otherwise provided herein), the Company shall permit an independent certified public accountant reasonably selected by Licensor and reasonably acceptable to the
Company to inspect (during regular business hours) the relevant records required to be maintained by the Company and its Affiliates and Sublicensee under this 

  
 11 

 
Article 7. In every case the accountant must have previously entered into a reasonable confidentiality agreement with both parties substantially in the form typically used in similar
circumstances limiting the disclosure and use of such information by such accountant to authorized representatives of the Parties and the purposes germane to this Article 7. Results of any such review shall be binding on both Parties absent manifest
error or fraud. Each Party agrees to treat the results of any such accountant’s review of the other Party’s records under this Article 7 as Confidential Information of the other Party subject to the terms of Article 13. If any review
reveals a deficiency in the calculation and/or payment of royalties or other payments by Company, then (a) the Company shall promptly pay Licensor the amount remaining to be paid, and (b) if such underpayment is by [***] percent ([***]%)
or more of the amount otherwise owed for the period audited, the Company shall pay the reasonable out-of-pocket costs and expenses incurred by Licensor in connection
with the review. 
 Article 8 Patent Prosecution and Maintenance 

 

	8.1	 Patent Prosecution and Maintenance. 

Licensor shall have the right and obligation at its sole expense to control the preparation, filing, prosecution and maintenance of all patents and patent
applications within the Patent Rights. If Licensor elects not to file any such patent application in any country, or decides to abandon any such pending application or issued patent in any country, Licensor shall provide written notice to the
Company, and the Company shall have the right at its sole expense to assume control of the preparation, filing, prosecution and maintenance of such patent application or patent at its own expense. 

 

	8.2	 Notification of Infringement. 

Each party shall notify the other party of any substantial infringement in the Territory known to such party of any Patent Rights and shall provide the other
party with the available evidence, if any, of such infringement. 
  

	8.3	 Enforcement of Patent Rights. 

Licensor shall have the right at its sole expense and in its sole discretion to control the enforcement of the Patent Rights against infringers. If, within
[***] months of receipt of written notice from Company that a Third Party is marketing in the Field in the Territory a product that infringes the Patent Rights, Licensor fails to abate the infringement or file suit to enforce such Patent Rights
against the infringing party, then the Company shall have the right to take whatever action it deems appropriate in its own name and, if required by law, in the name of Licensor to enforce such Patent Rights in the Field and Territory, and Licensor
shall reasonably cooperate with Company in the planning and execution of any such action to enforce the Patent Rights in the Field in the Territory. The party controlling any such enforcement action may not settle, or otherwise consent to an adverse
judgment in, such action that diminishes the rights or interests of the non-controlling party without the prior express written consent of the non-controlling party. All
monies recovered upon the final judgment or settlement of such action shall be shared, after reimbursement of expenses, in relation to the damages suffered by each party. If the Company does not receive sufficient monies from a final judgment or
settlement to cover its expenses for such suit, the Company shall have the right to credit up to [***] percent ([***]%) of such expenses against any royalties or other fees owing by the Company pursuant to Article 2 above. 

  
 12 

	8.4	 Cooperation. 

In any suit to enforce and/or defend the License Patent Rights pursuant to this Article 8, the party not in control of such suit shall, at the request and
expense of the controlling party, cooperate in all respects and, to the extent possible, have its employees testify when requested and make available relevant records, papers, information, samples, specimens, and the like. 

Article 9 Dispute Resolution 
  

	9.1	 Disputes 

  

	 	9.1.1	 The parties recognize that disputes as to certain matters may from time to time arise during the Term which
relate to either party’s rights and/or obligations hereunder or to the interpretation, performance, breach, or termination of this Agreement, (a “Dispute”). It is the objective of the parties to establish procedures to facilitate the
resolution of a Dispute in an expedient manner by mutual cooperation and without resort to litigation. To accomplish this objective, the parties agree to follow the procedures set forth in this Article 9 if and when a Dispute arises under this
Agreement. 

  

	 	9.1.2	 A Dispute among the parties will be resolved as recited in this Article 9. Any Disputes relating to this
Agreement shall be promptly presented to the Chief Executive Officers of Licensor and the Company, or their respective designees (who must be members of a party’s senior management) for resolution. From the date of referral of a Dispute to the
Chief Executive Officers or their designees of the parties and until such time as any matter has been resolved by the parties or has been finally settled by arbitration hereunder, the running of the cure periods (if any) as to which a party must
cure a breach that is part of the subject matter of any Dispute shall be suspended. In the event that the Chief Executive Officers of Licensor and the Company, or their respective designees, cannot after good faith negotiations resolve the Dispute
within [***] days (or such other period of time as mutually agreed to by the parties in writing) of being requested by a party to resolve a Dispute, the parties agree that such Dispute shall be resolved by binding arbitration in accordance with this
Article 9. 

  

	 	9.1.3	 If a party intends to begin arbitration to resolve such Dispute, such party shall provide written notice (the
“Arbitration Notice”) to the other party informing such other party of such intention and the issues to be resolved. Any arbitration hereunder shall be conducted pursuant to the Commercial Arbitration Rules of the American Arbitration
Association (“AAA”; such rules, the “AAA Rules”), except as modified herein. The arbitration shall be conducted by a panel of three (3) independent, neutral arbitrators that are industry experts experienced in the issues
comprising the Dispute and have no past, present or reasonably 

  
 13 

	 	
anticipated future affiliation with either party (the “Panel”). Company and Licensor shall each be entitled to select one (1) such arbitrator, with the two such arbitrators so
selected selecting the third such arbitrator. In the event either party fails to select its arbitrator within such [***] day period, the arbitrator selected by the other party within such [***] day period shall be entitled to select such arbitrator.
The arbitration shall take place in Houston, Texas and be conducted in English. The Panel shall apply the laws of the Commonwealth of Massachusetts, without regard to its conflicts of laws provisions. The Panel shall issue appropriate protective
orders to protect each party’s Confidential Information. If a party can demonstrate to the Panel that the complexity of the issue or other reasons warrant the extension of one or more timetables in the AAA Rules, the Panel may extend such
timetables but in no event shall the proceeding extend more than [***] months from the date of filing of the arbitration notice with the AAA. The Panel’s decision shall be in writing. The Panel shall have the authority to award any remedy
allowed by law, including but not limited to compensatory damages, pre-judgment interest, but not punitive or other damages and each party shall be deemed to have waived any right to such excluded damages.
Each party shall bear its own costs, fees and expenses in the arbitration and shall share equally the Panel’s fees, unless the Panel determines that its fees are to be paid by the non-prevailing party.
Notwithstanding anything to the contrary, without prejudice to the above procedures, either party may seek injunctive relief or other provisional judicial relief if, in its reasonable judgment, such action is necessary to avoid irreparable damage or
otherwise enforce its rights hereunder. 

  

	9.2	 Performance to Continue 

Each party shall continue to perform its obligations, and shall be permitted to continue to exercise its rights, under this Agreement pending final resolution
of any Dispute arising out of or related to this Agreement; provided, however, that a party may suspend performance of its obligations during any period in which the other party fails or refuses to perform its obligations. 

 

	9.3	 Determination of Patents and Other Intellectual Property 

Notwithstanding the foregoing, any dispute relating to the determination of validity of claims, infringement or claim interpretation relating to
Licensor’s Patent Rights shall be submitted exclusively to the courts. 
  

	9.4	 Statute of Limitation and Time-Based Defenses Tolled 

All applicable statutes of limitation and time-based defenses (such as estoppel and laches) shall be tolled while any arbitration proceedings are pending and
during any arbitration proceedings. The parties shall cooperate in taking any actions necessary to achieve this result. 

  
 14 

 Article 10 Term and Termination 

 

	10.1	 Term 

This Agreement shall become effective on the Effective Date and shall expire on the date of the expiration of the last to expire Royalty Term in any country in
the Territory (the “Term”), unless earlier terminated as provided in Articles 10.2, 10.3, or 10.5. 
  

	10.2	 Termination for Insolvency 

If the Company shall become bankrupt, or shall file a petition in bankruptcy, or if the business of the Company shall be placed in the hands of a receiver,
assignee or trustee for the benefit of creditors, whether by the voluntary act of the Company or otherwise, Company shall provide notice thereof to Licensor and License may, subject to the effects of and protections of any applicable
bankruptcy-related laws, rules, or regulations, terminate this Agreement upon notice to Company given within [***] business days of Licensor’s receipt of such notice. 
  

	10.3	 Termination for Material Breach 

Upon any material breach or default of this Agreement by the Company, Licensor shall have the right to terminate this Agreement and the rights, privileges and
license granted hereunder by giving [***] days prior written notice to the Company. Upon the expiration of the [***] day period, if the Company shall have not cured such breach or default, this Agreement shall, at the option of Licensor, terminate
upon written notice of Licensor. If a good faith dispute regarding termination is addressed pursuant to Article 10, this license shall remain in full force and effect until such dispute is resolved. All applicable statutes of limitation and
time-based defenses (such as estoppel and laches) shall be tolled while any good faith negotiation or mediation procedures are pending or ongoing. The parties shall reasonably cooperate in taking any actions necessary to achieve this result. 

 

	10.4	 Expiration of Royalty Term on a Country by Country Basis 

Upon the expiration of the Royalty Term in each country in the Territory, the Company will have an irrevocable, perpetual, paid up, royalty-free exclusive
license, with rights of sublicense (through multiple tiers), under all rights granted under this Agreement to use, have used, lease, import and export, offer to sell, sell have sold, produce, distribute and market Licensed Products in such country.

  

	10.5	 Termination for Convenience 

The Company shall have the right at any time to terminate this Agreement in its entirety or on a country-by-country basis, for any reason or no reason, by giving [***] days notice thereof in writing to Licensor. 
  

	10.6	 Consequences of Termination 

Upon the early termination of this Agreement by either party, the following shall occur: 

 

	 	10.6.1	 Subject to Article 10.6.2, the Company and its Affiliates (as the case may be) shall have no right to practice
within the Patent Rights or use any of the Patent Rights and Know-how, and all rights, title or interest in, or other incidents of ownership under, the Patent Rights and
Know-how shall revert to and become the sole property of Licensor, and the licenses granted under Article 2.1 shall automatically terminate. 

  
 15 

	 	10.6.2	 Notwithstanding Article 10.6.1, if this Agreement is terminated other than pursuant to Article 10.5, the
Company and its Affiliates may, after the effective date of such termination and continuing for a period not to exceed [***] months thereafter, sell all completed Licensed Products, and complete (or have completed) any Licensed Products in the
process of manufacture at the time of such termination and sell the same, provided that the Company: 

  

	 	(a)	 notifies Licensor of its decision within [***] days after the date it receives a notice of termination by
Licensor or the date it provides a notice of termination to Licensor, as the case may be; 

  

	 	(b)	 pays or cause to be paid to Licensor the royalties and other payments thereon as required by Article 6 of this
Agreement; and 

  

	 	(c)	 submits the reports required by Article 7 hereof. 

 

	 	10.6.3	 If the Company does not elect pursuant to Article 10.6.2 to sell-off or
distribute, as applicable, any existing inventory of Licensed Product, the Company shall, at Licensor’s election, either: 

  

	 	(a)	 sell all existing inventory of Licensed Product to Licensor at fair market value; or 

 

	 	(b)	 destroy all remaining inventory of Licensed Product in accordance with Applicable Laws and provide Licensor
with written proof of destruction sufficient to comply with Applicable Laws. 

  

	 	10.6.4	 Notwithstanding anything to the contrary, each sublicense granted under this Agreement by the Company or its
Affiliates to a Sublicensee shall, to the extent not imposing obligations on Licensor in excess of those contained herein, survive such termination and be automatically assigned to Licensor as provided for in Article 2, in order to provide for the
applicable Sublicensees’ continued enjoyment of their rights under such sublicenses. 

  

	10.7	 Partial Termination 

Upon the early termination of this Agreement by either party in respect of a country, the terms of Article 11.6 shall apply in respect of such country. 

 

	10.8	 Survival 

Upon termination of this Agreement for any reason, nothing herein shall be construed to release either party from any obligation that matured prior to the
effective date of such termination, or such party’s obligations under Articles 6 and 7, and the following provisions shall survive such termination: Articles 11, 12.3, 13 and 14. Additionally, the Licensor’s rights pursuant to Article 4.2
shall survive the termination of this Agreement. 

  
 16 

 Article 11 Limitation of Liability, Indemnity 

 

	11.1	 NO IMPLIED WARRANTIES 

 

	 	11.1.1	 LICENSOR DOES NOT MAKE AND EXPRESSLY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES OF ANY KIND, EITHER EXPRESS
OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND VALIDITY OF PATENTED RIGHTS CLAIMS, ISSUED OR PENDING. 

 

	 	11.1.2	 NOTHING HEREIN SHALL BE CONSTRUED AS A REPRESENTATION OR WARRANTY BY LICENSOR TO THE COMPANY THAT THE PATENT
RIGHTS AND KNOW-HOW ARE NOT INFRINGED BY ANY THIRD PARTY, OR THAT THE PRACTICE OF SUCH RIGHTS DOES NOT INFRINGE ANY INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. 

 

	11.2	 Indemnity 

  

	 	11.2.1	 The Company agrees to defend, indemnify and hold harmless Licensor, its Affiliates, directors, employees and
officers (“Licensor Indemnitees”) from and against all liability, demands, damages, including without limitation reasonable legal fees and expenses, and losses including death, personal injury, illness or property damage arising directly
out of the Company’s use, manufacture, sale, or other disposition of Licensed Products under the terms of this Agreement, to the extent not resulting from any Licensor Indemnitee’s breach of this Agreement, negligence, willful misconduct,
or failure to comply with Applicable Laws. 

  

	 	11.2.2	 Licensor agrees to defend, indemnify and hold harmless the Company, its Affiliates, directors, employees, and
officers (“Company Indemnitees”) from and against all liability, demands, damages, including without limitation reasonable legal fees and expenses, and losses including but not limited to death, personal injury, illness or property damage
arising directly out of any Licensor Indemnitee’s breach of this Agreement, negligence, willful misconduct, or failure to comply with Applicable Laws. 

  

	11.3	 LIMITATION OF LIABILITY 

EXCEPT WITH REGARD TO DAMAGES ARISING FOR INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS, BREACHES OF ARTICLE 12.3 OR 13, AND ANY DUTY TO INDEMNIFY FOR SPECIAL,
PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES UNDER ARTICLE 11.2.1 OR 11.2.2, IN NO EVENT SHALL EITHER PARTY OR THEIR AFFILIATES BE LIABLE FOR SPECIAL, PUNITIVE, 

  
 17 

 
INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY AND IRRESPECTIVE OF WHETHER SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF ANY SUCH
LOSS OR DAMAGE. 
 Article 12 Use of Names and Publication 
  

	12.1	 Use of Name 

Nothing contained in this Agreement shall be construed as granting any right to the Company or its Affiliates to use in advertising, publicity, or other
promotional activities any name, trade name, trademark, or other designation of Licensor or any of its units (including contraction, abbreviation or simulation of any of the foregoing) without the prior, written consent of Licensor; provided that
Company may identify Licensor as the licensor under this Agreement without such consent to actual or potential investors, investment bankers, acquirers, acquisition targets, and strategic partners, and where the use of such names may be required by
Applicable Law. 
  

	12.2	 No Agency 

Nothing herein shall be deemed to establish a relationship of principal and agent between Licensor and the Company, nor any of their agents or employees for
any purpose whatsoever. This Agreement shall not be construed as creating a partnership between the Licensor and the Company, or as creating any other form of legal association or arrangement, which would impose liability upon one party for the act
or failure to act of the other party. 
  

	12.3	 Publication 

In the event that the Company or any Affiliate, employee, officer, director, or shareholder thereof desires to publish or disclose, by written, oral or other
presentation, any information about the Technology or included in the Patent Rights, Know-how, or any material information related thereto, the Company shall provide the Licensor with a copy of the proposed
publication, presentation, or disclosure at least [***] days prior to its submission for presentation, publication, or disclosure. The Licensor may request that the Company, no later than [***] days following the receipt of such proposed
publication, presentation, or disclosure, (i) delay such presentation, publication or disclosure for up to an additional [***] days in order to enable the Licensor to file, or have filed on their behalf, a patent application, copyright or other
appropriate form of intellectual property protection related to the information to be disclosed or request that the Company do so, (ii) remove the Licensor’s Confidential Information from such presentation, publication or disclosure,
and/or (iii) make any other reasonable changes to such proposed publication, presentation, or disclosure, as applicable. Upon receipt of such request, the Company shall (i) arrange for a delay of such presentation, publication or
disclosure until such time as the Licensor or the Company have filed, or had filed on its behalf, such patent application, copyright or other appropriate form of intellectual property protection in form and in substance reasonably satisfactory to
the Company and Licensor, (ii) remove the Licensor’s Confidential Information from such presentation, publication or disclosure, and/or (iii) reasonably consider any other reasonable changes proposed by the Licensor. If Company does
not receive any request from the Licensor to delay such presentation, publication or disclosure, the Company may submit such material for presentation, publication or other form of disclosure, subject to Company’s obligations under Article 15.

  
 18 

 Article 13 Confidentiality 

 

	13.1	 Confidentiality and Non-Use 

Any proprietary or confidential information relating to the Technology, Patent Rights, Know-how (including but not
limited to patent prosecution documents relating to Patent Rights), reports and records provided under Articles 3.1, 4.2 and 7, and any other reasonably confidential or proprietary information concerning a party’s business or technology
disclosed to the other party under this Agreement collectively constitute the “Confidential Information.” Neither party will use the Confidential Information for any purpose unrelated to the exercise of their rights or fulfillment of their
obligations under this Agreement, and will hold it in confidence during the Term and for a period of [***] years after the termination or expiration date of this Agreement. Each party shall exercise with respect to such the Confidential Information
the same degree of care as the party exercises with respect to its own confidential or proprietary information of a similar nature, but in no event less than reasonable care, and shall not disclose it or permit its disclosure to any Third Party
(except to those of its employees, consultants, or agents who are bound by a substantially similar obligation of confidentiality of this Agreement). However, such undertaking of confidentiality shall not apply to any information or data which: 

 

	 	13.1.1	 The receiving party receives without obligation of confidentiality at any time from a third-party lawfully in
possession of same and having the right to disclose same; 

  

	 	13.1.2	 is, as of the date of this Agreement, in the public domain, or subsequently enters the public domain through no
fault of the receiving party; 

  

	 	13.1.3	 is independently developed by the receiving party as demonstrated by written evidence without reference to or
benefit of information disclosed to the receiving party by the disclosing party; 

  

	 	13.1.4	 is disclosed pursuant to the prior written approval of the disclosing party; or 

 

	 	13.1.5	 is required to be disclosed pursuant to Applicable Law or legal process (including, without limitation, to a
governmental authority) provided that recipient will (i) give prior written notice of such required disclosure to the other party, to the extent reasonably practicable, (ii) give reasonable assistance to the other party, as requested
thereby, seeking confidential or protective treatment thereof, and (iii) only disclose such Confidential Information to the extent required by such Applicable Law or legal process. 

 

	13.2	 Material Non-Public Information 

The Company understands that it is the intent of the Licensor to register its capital stock on a national securities exchange or the Over the Counter Bulletin
Board and accordingly, the Licensor understands that confidential information provided to it by the Company pursuant to the terms of this Agreement may constitute “material non-public information”
concerning the Company. 

  
 19 

 Article 14 Miscellaneous Provisions 

 

	14.1	 Assignment 

This Agreement and the rights and duties appertaining hereto may not be assigned by either party without first obtaining the written consent of the other
party, which consent shall not be unreasonably withheld. Any such purported assignment without the written consent of the other party shall be null and of no effect. Notwithstanding the foregoing, each party hereto may assign this Agreement without
the consent of the other (i) to a purchaser, merging, or consolidating corporation, or acquirer of all or substantially all of such party’s assets or business (or that portion thereof to which this Agreement relates) and/or pursuant to any
reorganization of such party or (ii) to an Affiliate of such party. 
  

	14.2	 Binding Nature and Inurnment 

This Agreement will not be binding upon the parties until it has been signed below on behalf of each party, in which event, it shall be effective as of the
Effective Date. As of the Effective Date, this Agreement is binding upon and inures to the benefit of the parties and their respective permitted successors and assigns. 
  

	14.3	 Counterparts; Facsimile 

This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument. This Agreement may be signed and delivered to the other party by facsimile signature; such transmission will be deemed a valid signature. 
  

	14.4	 Entire Agreement; Amendment 

The parties hereto acknowledge that this Agreement, including the Exhibits, Schedules and documents incorporated by reference, sets forth the entire agreement
and understanding of the parties hereto as to the subject matter hereof, and shall not be subject to any change of modification except by the execution of a written instrument subscribed to by the parties hereto and shall supersede all previous
communications, representations or understandings, either oral or written, between the parties relating to the subject matter hereof. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the parties hereto
unless reduced to writing and signed by the respective authorized officers of the parties. 
  

	14.5	 Force Majeure 

Neither party is responsible for delays resulting from causes beyond its reasonable control, including without limitation fire, explosion, flood, war, strike,
or riot, provided that the nonperforming party uses commercially reasonable efforts to avoid or remove those causes of nonperformance and continues performance under this Agreement with reasonable dispatch whenever the causes are removed. 

  
 20 

	14.6	 Further Assurances 

From time to time during the Term, at the request of either party, the other party shall execute and deliver such documents and take such other action as the
requesting party may reasonably request to consummate more effectively the transactions contemplated hereby. 
  

	14.7	 Headings 

The headings of the several articles are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or
interpretation of this Agreement. 
  

	14.8	 Law 

This Agreement shall be construed, governed, interpreted and applied in accordance with the laws of the Commonwealth of Massachusetts, without regard to
principles of conflicts of laws. 
  

	14.9	 Payments, Notices and Other Communications 

Any payment, notice or other communication required or permitted to be given pursuant to this Agreement shall be in writing and sent by certified first class
mail, postage prepaid, by hand delivery or by facsimile if confirmed in writing, in each case effective upon receipt, at such party’s principal place of business or as otherwise designated by written notice given to the other party 

 

	14.10	 Payment of Own Fees and Expenses 

Each of the Company and Licensor shall be responsible for their own expenses relating to the preparation and consummation of this Agreement and, except as
specified herein, the agreements and transactions contemplated hereby. 
  

	14.11	 Severability 

The provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under
any controlling body of law, such invalidity or unenforceability shall not in any way affect the validity or enforceability of the remaining provisions hereof. 
  

	14.12	 Waiver 

The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver
of that right or excuse a similar subsequent failure to perform any such term or condition by the other party. Any waiver of any rights or failure to act in a specific instance relates only to that instance and is not an agreement to waive any
rights or fail to act in any other instance. 
 [Signature page to follow.] 

Schedule 1.18: Patent Rights 

[NOTE: To be completed/updated by Licensor] 

  
 21 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement, in triplicate by proper persons
thereunto duly authorized. 
  

			
	ADVANTAGENE, INC.	  	VENTAGEN, LLC
		
	By:                                     
                                 	  	By:                                     
                                 
		
	Name:                                     
                            	  	Name:                                     
                            
		
	Title:                                     
                              	  	Title:                                     
                              
		
	Date:                                     
                              	  	Date:                                     
                              

 Ellka Holding, LLC d/b/a Advantagene Holdings, LLC hereby consents to this Agreement and acknowledges and agrees that the
Original License is hereby cancelled and terminated, without breach, and is hereafter void and shall no longer be in force and effect. 
 ELLKA HOLDING
,LLC 
  

	
	By:                                     
                                 
	
	Name:                                     
                            
	
	Title:                                     
                              
	
	Date:                                     
                              

  
 22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]